Seed startup

Who invested in Verse Medical

One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

IT Services

Y Combinator: S18

Funding summaryUpdated 26 Oct 2026

$3.0Mraised across 1 round since 2021, from 1 source

Latest round
Seed, $3.0MMar 2021
Investors
5
See who backed them

The rounds

  1. Mar 2021

Everyone who backed them

Y CombinatorAccelerator1round
Soma CapitalVC firm1round
FundersClubVC firm1round
Abstract VenturesVC firm1round
Edward LandoAngel1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 5 firms list Verse Medical as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

Sapphire VenturesVC firmPer its own site
SignalFireVC firmPer its own site
Webb Investment NetworkFamily officePer its own site
Justin MateenVC firmPer its own site
Wayfinder VenturesVC firmPer its own site

Quick answers about Verse Medical

Who invested in Verse Medical?

Verse Medical's investors include Y Combinator, Soma Capital, FundersClub, Abstract Ventures and Edward Lando.

How much has Verse Medical raised?

Verse Medical has raised $3.0M across 1 round since 2021.

When did Verse Medical last raise?

Verse Medical's most recent round was a Seed of $3.0M in Mar 2021.

What was Verse Medical's biggest round?

Its most recent round, $3.0M in Mar 2021, is also its largest on record.

Who backed Verse Medical first?

Verse Medical's first round on record, in Mar 2021, was backed by Y Combinator, Soma Capital and FundersClub and 2 others.

What stage is Verse Medical at?

Verse Medical's latest named round is a Seed, in Mar 2021.

Companies like Verse Medical

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.